The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype
NCT ID: NCT04171167
Last Updated: 2023-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
88 participants
INTERVENTIONAL
2017-04-04
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of our study is to evaluate the relation of chronic rhino sinusitis (CRS) severity and inflammatory status to nNO, maxillary sinus NO, nitrite, nitrate and cone beam computed tomography (CBCT).
Three groups (22 patients in each) of referred patients and and 22 healthy volunteers are recruited. Patients are grouped according to the CBCT score and viewed three times in 4-6 weeks intervals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation Effects of Nasal Nitric Oxide Measurements Are Associated With Atopy Status in Chronic Nasal Inflammation
NCT01295866
Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis
NCT01018030
NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP
NCT03963648
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
NCT00584662
Predictive Factors in Chronic Rhinosinusitis With Nasal Polyps
NCT06459622
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Frequently treated acute rhino sinusitis
Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
Fluticasone Propionate
three visits: 0, after washout, after FP usage
CRSsNP
Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score \< 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
Fluticasone Propionate
three visits: 0, after washout, after FP usage
Severe CRSsNP and CRSwNP
Meets the European position paper criteria of CRS and not included in the first two groups.
Fluticasone Propionate
three visits: 0, after washout, after FP usage
Healthy volunteers
No nasal symptoms or complaints. No interventions done.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluticasone Propionate
three visits: 0, after washout, after FP usage
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are referred to ENT clinic due to chronic rhinosinusitis (EPOS criteria) or repeatedly diagnosed and treated acute rhinosinusitis
Exclusion Criteria
* Septal deviation that would need an operation to correct the air flow
* Other severe disease that could pose a risk for the patient during the measurements based on the judgement of the treating physician
* Pregnancy or breastfeeding
* Allergy to used medications
* Inability to co-operate or to tolerate manipulation of the nose
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere University Hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R17011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.